Psilocybin in pharmacotherapy of obsessive-compulsive disorder

Pharmacol Rep. 2024 Oct;76(5):911-925. doi: 10.1007/s43440-024-00633-1. Epub 2024 Aug 1.

Abstract

Obsessive-compulsive disorder (OCD) is a chronic mental disease that affects approximately 2% of the population. Obsessions and compulsions are troublesome for patients and may disturb their everyday activities. The pathogenesis of this disease is still not fully elucidated, but dysfunctions of serotonin-, dopamine- and glutamate-mediated neurotransmission together with early maladaptive schemas seem of importance. Pharmacological treatment includes drugs affecting the serotoninergic, dopaminergic, and glutamatergic systems, such as selective serotonin reuptake inhibitors (SSRIs). Providing that up to 40% of patients with OCD are resistant to the currently available medications, there is a need for novel and effective therapies. Recent discoveries suggest that psilocybin, a non-physically addictive psychoactive substance, may ameliorate disease symptoms. When used in appropriate doses and under strict clinical control, psilocybin appears as a valuable treatment for OCD. This narrative article provides a thorough overview of OCD's etiology, current treatment options, and the emerging evidence supporting psilocybin's efficacy in managing OCD symptoms.

Keywords: Obsessive-compulsive disorder; Psilocin; Psilocybin; Serotonin.

Publication types

  • Review

MeSH terms

  • Animals
  • Hallucinogens* / pharmacology
  • Hallucinogens* / therapeutic use
  • Humans
  • Obsessive-Compulsive Disorder* / drug therapy
  • Psilocybin* / pharmacology
  • Psilocybin* / therapeutic use
  • Selective Serotonin Reuptake Inhibitors / pharmacology
  • Selective Serotonin Reuptake Inhibitors / therapeutic use

Substances

  • Psilocybin
  • Hallucinogens
  • Selective Serotonin Reuptake Inhibitors